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Abstract 
We report a case of a patient with concurrent myotonic dystrophy and recurrent pleomorphic adenoma and hypothesize the association 
between both diseases. A 58-year-old man with classic myotonic dystrophy type 1 was diagnosed with pleomorphic adenoma. Appropriate 
treatment was commenced. Massive recurrences occurred within 15, 28 and 22 months respectively, after repeated surgical removal. Three 
case reports on similar occurrences of synchronous myotonic dystrophy and pleomorphic adenoma are discussed and an association between 
both disease entities is hypothesized. A conceivable association between myotonic dystrophy and pleomorphic adenoma is hypothesized by 
upregulation of the Wnt/Beta-catenin signaling pathway, initiated by a decreased expression of microRNA, pleomorphic adenoma gene 1 
induced Beta-catenin accumulations and alterations in tumor suppressor genes and oncogenes due to RNA processing defects induced by the 
expanded repeat in the DMPK gene. 
© 2020 The Authors. Published by Elsevier B.V. 
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1. Background 
Myotonic Dystrophy type 1 (DM1) is a rare autosomal 
dominant disease with an estimated prevalence of 1:8.000. 
DM1, formerly known as Steinert disease, is one of 
the two major forms of Dystrophia Myotonica (DM), 
resulting from an unstable Cytosine-Thymine-Guanine 
(CTG) trinucleotide repeat expansion in the 3 ′ -untranslated 
region of the Dystrophia Myotonica Protein Kinase ( DMPK ) 
gene, on chromosome 19q 13.3. Generally, longer CTG 
repeat expansions correlate with an earlier age at onset and 
more severe disease [1] . The repeat expansion is however 
mitotically unstable in individuals with DM1, leading to 
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somatic mosaicism in the CTG repeat length between 
various tissues and organs, partially explaining the wide 
phenotypic variability. The effect of the expanded CTG repeat 
remains complex, although it is thought this mainly occurs 
through abnormal RNA transcript processing in antagonistic 
proteins of splicing events disrupted in patients with DM1 
[2–4] . Other additional factors contributing to DM1 are still 
being studied and remain unknown. The disease is mainly 
characterized by muscle weakness and myotonia but affects 
other organ systems as well, causing early onset cataract, 
cardiac conduction disturbances, respiratory insufficiency, 
insulin resistance and infertility. Patients with DM1 have an 
increased risk of developing benign and malignant tumors. 
The most commonly associated and described neoplasm 
being the pilomatrixoma, which is a rare benign calcifying 
cutaneous tumor [5] . They are however also at an increased 
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Fig. 1. T2-weighted Magnetic Resonance Image (MRI) (December 2011) of a large pleomorphic adenoma in the right deep parotid lobe indicated with the 
white arrow in the coronal (a) and axial (b) planes. 
risk for endometrium, brain, ovary, colon, testicular and 
thyroid tumors, choroidal melanoma and possible prostate 
cancer [5–8] . Additionally it was recently described that, in 
comparison to 13.085 matched DM1-free individuals, salivary 
gland adenomas occurred at a relatively high frequency in 
927 DM1 patients [9] . 
Salivary gland tumors, however, are rare, accounting for 
approximately 3 cases per 100.000 inhabitants every year 
[10] . Most salivary gland tumors arise in the parotid gland, of 
which 75% is benign and 25% malignant [10] . Pleomorphic 
adenoma is the most common benign salivary gland tumor 
and usually presents as a slowly growing painless swelling. 
However, pleomorphic adenomas may undergo malignant 
transformation even after many years. The risk for malignant 
transformation increases up to 10% after 15 years. Therefore, 
pleomorphic adenomas are surgically removed. 
Recurrences of pleomorphic adenomas are a challenging 
problem and occur in approximately 2% of patients after 
a superficial parotidectomy, usually after 7–10 years. A 
total parotidectomy reduces the recurrence rate to 0.4% 
[11–13] . The likelihood of recurrence is higher in relatively 
young patients, when resection margins are positive and 
when the tumor capsule was ruptured during surgery 
[12 , 14] . Surgical removal of a recurrence with as much 
normal surrounding gland tissue as possible, with or 
without postoperative radiotherapy, consecutively reduces the 
probability of rerecurrences significantly [12 , 15] . 
In addition to three case reports describing the occurrence 
of pleomorphic adenoma in DM1 patients [16–18] , here 
we report a patient with DM1 and multiple reoccurring 
pleomorphic adenomas and highlight a hypothesis that 
associates both diseases. 
2. Case report 
A 58-year-old man was referred to the Ear, Nose, and 
Throat (ENT) department in November 2011 by his general 
practitioner with an increasing painless swelling in the right 
parotid region since 5 months. The patient was known to 
have classic DM1 since 1991 (repeat size unknown) based on 
clinical features and family history as his mother and brother 
were diagnosed with DNA confirmed DM1. The DM1 was 
characterized by a mild muscle weakness in the distal arms 
and legs, a typical myopathic face and a reduced processing 
speed. The history of the patient mentioned an ileus in 2003 
which was surgically treated, proctitis, gout and obstructive 
sleep apnea. There was no family history of cancer. The 
patient did not smoke or drink alcohol. ENT examination 
revealed a swelling in the right parotid region with indefinable 
boundaries. No other abnormalities were found. Magnetic 
Resonance Imaging (MRI) illustrated a large space occupying 
lesion in the deep parapharyngeal right parotid lobe without 
invasion of surrounding tissues ( Fig. 1 ). Fine needle aspiration 
(FNA) of the lesion, showed a pleomorphic adenoma without 
malignant features. An external deep parotid dissection was 
performed in January 2012; no complications, i.e. facial nerve 
damage, occurred. Histology showed a radically removed, 
entirely encapsulated pleomorphic adenoma of 30 mm. 
In April 2013, 15 months after initial surgery, the patient 
detected a painful swelling in the right submandibular region. 
An ultrasound showed two submandibular lesions of 11 mm 
and 16 mm. Multiple cystic structures suspect for recurrent 
pleomorphic adenomas in the right prestyloid parapharyngeal 
space, reaching until the right submandibular region were seen 
on MRI ( Fig. 2 ). FNA of the two submandibular lesions 
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Fig. 2. T2-weighted MRI (June 2013) showing multiple cystic structures 
in the right prestyloid parapharyngeal space, reaching until the right 
submandibular region in the coronal plane, suspect for recurrent pleomorphic 
adenomas Fig. 2 . 
was suspicious for a pleomorphic adenoma. Therefore in 
June 2013, a right re-parotidectomy was performed in which 
multiple histological confirmed pleomorphic adenomas were 
resected. The facial nerve could again be preserved. Due to 
some remaining lesions which were impossible to resect, the 
patient received additional postoperative radiation therapy and 
was closely followed up. 
Throughout the follow-up period multiple MRI’s showed 
stable disease until October 2015, when the patient developed 
renewed pain in the right parotid region. Meanwhile he 
felt that he could not close his right eye properly and 
that the right side of his mouth drooped, suggesting facial 
nerve involvement. However, on physical examination a facial 
nerve palsy was hard to assess, due to the DM1. MRI 
showed an increase of the lesions in the right parapharyngeal 
space and new lesions in the deep right parotid lobe. 
Therefore, in December 2015, a deep right lobe parotidectomy 
in combination with a mandibular split and temporary 
tracheotomy was performed to remove all lesions, sacrificing 
the right facial and lingual nerve. Histological analysis 
showed re-recurrence of the pleomorphic adenomas without 
any malignant degeneration. Additional radiation therapy was 
not feasible this time, because of the patients’ post-surgical 
weakened physical state. 
By the end of October 2017, 22 months after the last 
surgery, a small right pre-auricular painful swelling and 
two small swellings in the previous scar had appeared. An 
MRI to determine the extent of the swellings showed a 
severely extended tumor, suspicious of pleomorphic adenoma, 
in mainly the right parotid region and right parapharyngeal 
space of 88 ×37 mm ( Fig. 3 ). The tumor extended into the 
stylomastoid foramen, foramen ovale and mandibular foramen 
and caused vigorously medialisation of the nasopharynx 
and cranial tonsil loge. Thus even though all pleomorphic 
adenomas appeared to be surgically removed in December 
2015, 22 months later a third massive recurrence, within 
4.5 years after primary surgery, was confirmed by FNA. 
Several days after the MRI, the patient suddenly died due 
to aspiration. 
3. Discussion 
Despite adequate multiple resections and postoperative 
radiation therapy after the first recurrence, our patient 
experienced two rerecurrences. While multiple recurrences 
of pleomorphic adenoma have been reported, recurrence 
within 15 months after initial radical surgical removal, and 
rerecurrence within 28 and 22 months respectively after 
repeated extended surgery and additional radiation therapy is 
rare [11] . This unusual progressive and aggressive recurrence 
behavior and short time period between recurrences and 
re-recurrences, raised the suspicion of an association with the 
coexisting DM1. An extended literature search in PubMed 
with the terms ‘myotonic dystrophy’ OR ‘Steinert’ AND 
‘pleomorphic adenoma’ resulted in three additional cases. 
Johannesson [16] was the first to report the coexistence 
of myotonic dystrophy and pleomorphic adenoma in two 
women in 1978, statistically arguing that the probability 
of coincidence due to chance was too small, suggesting 
there had to be factors predisposing to parotid neoplasms 
in myotonic dystrophy. In 1998 Ogata et al. [17] suggested 
that the extension of CTG repeats was related to active 
cell division and to the occurrence of tumors in patients 
with myotonic dystrophy. They used a Southern blot 
analysis showing that the CTG repeat in the pleomorphic 
adenoma tumor DNA of a 60-year-old patient was more 
expanded than in the other parotid gland. Insights in the 
causative role of somatic mosaicism, the presence of a 
genetically distinct cell population within an organism [19] , 
has previously been described in cancer and many non- 
tumorous neurodegenerative and complex diseases [20–24] . 
Draper and Pickles [18] described another two cases of 
patients with myotonic dystrophy and pleomorphic adenoma 
in 2000, of which one concerned a 9-year-old girl. They 
proposed that the occurrence of pleomorphic adenoma at such 
a young age in a girl with congenital myotonic dystrophy was 
so rare, that an association between the two disease entities 
was highly likely. 
Additional literature research learned that pilomatrixoma, 
a benign calcifying cutaneous tumor, which is the most 
common neoplasm in patients with DM1 [5] , contains somatic 
mutations in the gene encoding for β-catenin ( CTNNB1 ), 
resulting in an accumulation of β-catenin [25] . As component 
of the Wnt/ β-catenin signaling pathway, which is crucial in 
927 
I.M.J. Pruijn, C.M.L. van Herpen, S.A.H. Pegge et al. Neuromuscular Disorders 30 (2020) 925–929 
Fig. 3. T2-weighted MRI (November 2017) revealing massive pleomorphic adenomas in the right parotid region and right parapharyngeal space. The tumor 
extends into the stylomastoid foramen, foramen ovale and mandibular foramen, causing vigorously medialisation of the nasopharynx and cranial tonsil loge. 
human organ development and involved in tumor progression 
of many cancers, an accumulation of β-catenin up regulates 
the Wnt/ β-catenin signaling pathway. 
Accumulations of β-catenin have also been shown in 
CTNNB1 -mutated thyroid carcinoma, one of the other cancers 
frequently seen in patients with DM1 [5 , 8] . Many tumors 
however accumulate β-catenin in the absence of mutations 
in CTNNB1 , suggesting other sources leading to β-catenin 
accumulations [26] . 
In pleomorphic adenomas, the pleomorphic adenoma gene 
1 (PLAG1) seems to play a crucial role in tumorgenesis 
and β-catenin accumulation. Zhao et al. [27] used transgenic 
mice to demonstrate that overexpression of PLAG1 induces 
upregulation of β-catenin and thereby the Wnt/ β-catenin 
signaling pathway, leading to the development of pleomorphic 
adenomas in the parotid glands of mice. 
The exact pathogenetic and molecular carcinogenesis 
mechanisms in DM1 remain undefined. The most appealing 
hypothesis yet is the alteration of oncogenes or tumor 
suppressor genes due to RNA processing defects induced by 
the expanded repeat in the DMPK gene, increasing the risk 
of neoplasm development. Fernández-Torrón et al. observed a 
decrease in the expression of the microRNA-200/microRNA- 
141 tumor suppressor family in women with DM1 in 
comparison to a control of healthy people [28] . Recent 
evidence shows that microRNA-200 is a key modulator in 
the Wnt-signaling pathway and capable of directly interacting 
with CTNNB1 (the gene encoding β-catenin) to suppress 
Wnt/ β-catenin signaling [29 , 30] . A decreased expression 
of this microRNA might thus lead to tumor formation 
and the occurrence of pleomorphic adenoma in patients 
with DM1. Future studies investigating the exact pathogenic 
mechanisms underlying pleomorphic adenomas and tumor 
behavior in patients with DM1 are needed to establish targeted 
therapeutic interventions and guide clinical management and 
follow-up. 
Currently, clinicians treating patients with DM1 are 
advised by the consensus-based care recommendations to 
train patients in detecting small hard lumps under the 
skin, near the hairline and on the neck, suspicious for 
pilomatrixomas [31] . We advise them however to also be 
aware of lumps in the parotid area suspicious for pleomorphic 
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adenoma and advise them to refer these patients for evaluation 
and clinical work-up as pleomorphic adenoma usually need 
surgical treatment to prevent malignant transformation. 
4. Conclusion 
Patients with DM1 are known to have an increased 
risk of benign and malignant tumors of the endometrium, 
brain, ovary, colon, testis, thyroid, possibly the prostate 
as well as an increased risk of choroidal melanoma. In 
addition our case highlights a possible association between 
DM1 and reoccurring pleomorphic adenomas. While the 
exact underlying pathologic mechanism in the pathogenesis 
for DM1 and concurrent neoplasms remains unclear, the 
hypothesis of an unsuppressed Wnt/ β-catenin signaling 
pathway via decreased expression of micro-RNA and up 
regulation of β-catenin by PLAG1, in combination with 
the alteration of tumor suppressor genes and oncogenes 
due to RNA processing defects induced by the expanded 
repeat in DMPK might lead to the formation of myotonic 
dystrophy associated pleomorphic adenomas. In this light we 
advise clinicians treating patients with DM1 to be aware of, 
and evaluate lumps in the parotid region as these may be 
pleomorphic adenomas in need for surgical treatment. 
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